Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group

Robert Perneczky, Oren Tene, Johannes Attems, Panteleimon Giannakopoulos, M. Arfan Ikram, Antonio Federico, Marie Sarazin and Lefkos T. Middleton

Abstract

Background: Long before Alzheimer’s disease was established as the leading cause of dementia in old age, cerebrovascular lesions were known to cause cognitive deterioration and associated disability. Since the middle of the last century, different diagnostic concepts for vascular dementia and related syndromes were put forward, yet no widely accepted diagnostic consensus exists to date.

Discussion: Several international efforts, reviewed herein, are ongoing to define cognitive impairment due to cerebrovascular disease in its different stages and subtypes. The role of biomarkers is also being discussed, including cerebrospinal fluid proteins, structural and functional brain imaging, and genetic markers. The influence of risk factors, such as diet, exercise and different comorbidities, is emphasised by population-based research, and lifestyle changes are considered for the treatment and prevention of dementia.

Conclusion: To improve the diagnosis and management of vascular cognitive impairment, further progress has to be made in understanding the relevant pathomechanisms, including shared mechanisms with Alzheimer’s disease; bringing together fragmented research initiatives in coordinated international programs; testing if known risk factors are modifiable in prospective interventional studies; and defining the pre-dementia and pre-clinical stages in line with the concept of mild cognitive impairment due to Alzheimer’s disease.

Keywords: Cerebrovascular disease, Dementia, Cognition, Biomarker, Risk factor, Neuroimaging, Cerebrospinal fluid, Magnetic resonance imaging, Genetics, CADASIL

Background

The current paper presents the consensus of the Diagnostic Criteria Working Group of the 9th International Congress on Vascular Dementia, held on October 16–18, 2015 in Ljubljana, Slovenia. The concept that late-life dementia can occur in the context of cerebrovascular disease has been known since the nineteenth century [1, 2], and up until the 1960s, cerebral arteriosclerosis as well as widespread white matter lesions in patients with longstanding hypertension were seen as the main cause of dementia in older individuals [1]. This view was challenged by Blessed et al. [3] and others, who suggested that Alzheimer’s disease (AD) neuropathology is the landmark neuropathological feature in the majority of age-related dementia cases. This paradigm shift led to the development of the concept of multi-infarct dementia (e.g. dementia following multiple brain infarcts), which subsequently was used to define vascular dementia (VaD) in several international classification systems such as the Diagnostic and...
Statistical Manual of Mental Disorders 4th edition (DSM-IV) and the International Classification of Diseases and Related Health Problems, 10th edition (ICD-10). However, subsequent studies suggested that the majority of VaD cases were caused by subcortical cerebrovascular changes, rather than by large cortical infarcts [3]. As a result of these conflicting views, different sets of criteria for VaD were developed, including the National Institute of Neurological Disorders and Stroke – Association Internationale pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) [4] and the State of California Alzheimer’s Disease Diagnostic and Treatment Centers criteria [4], as well as criteria for specific subtypes such as subcortical VaD [5]. Parallel to similar developments in the AD field, it was recognised that cerebrovascular disease frequently co-occurs with other pathological changes in the majority of patients over the age of 75 [6], which is the age group when over 70 % of dementia cases occur [7]. Simultaneously, there was controversy regarding the use of the term dementia, which became synonymous with the concept of AD dementia, requiring prominent memory deficits in addition to impairment in at least one other cognitive domain. Nevertheless, this pattern of cognitive decline is not necessarily applicable in patients with VaD [8]. Furthermore, the need for inclusion of pre-dementia changes within a broader nosological concept similar to mild cognitive impairment due to AD was also acknowledged. Based on these considerations, the term ‘vascular cognitive impairment’ (VCI) was proposed [9], which accounts for the heterogeneous nature (and degrees) of cognitive deficits related to prominent cerebrovascular pathologies. Vascular mild cognitive impairment [6] or vascular cognitive impairment, no dementia [7] were terms proposed to categorise the early clinical stages. However, despite VCI being clearly a step in the right direction, it has not been widely adopted and parallel classification systems are still being employed.

Validated clinical diagnostic criteria are important to identify suitable subjects for clinical trials in order to develop new drugs for VCI. Their relevance increases further if treatment strategies are to be developed that target specific pathogenic cerebrovascular mechanisms leading to VCI [10]. Furthermore, lifestyle interventions and other non-pharmacological approaches can only be developed if the target populations are clearly defined [8]. Current efforts towards a consensus on diagnostic criteria and guidelines to account for the heterogeneous nature of VCI, such as the recent International Society for Vascular Behavioural and Cognitive Disorders statement [11], must be encouraged. However, despite considerable recent advances, there are significant gaps in our understanding of the neurobiological mechanisms underpinning the various dementia forms [12]. Further research is therefore required before definitive criteria and guidelines can be formulated. Additionally, the success of such criteria will ultimately depend on a robust pathological and clinical validation and the support of the international research community.

The present paper summarises recent major developments in relation to the clinical diagnosis of VCI. We discuss how this entity is handled in the new DSM-V criteria, how our knowledge about the relevant neuro-pathological changes impacts on the concepts surrounding this diagnosis, and what role fluid and neuroimaging biomarkers play. Further, we briefly summarise the current knowledge about risk factors and how they should be addressed in the context of the clinical diagnostic process. Finally, rare genetic causes of VCI/VaD are discussed and recommendations are provided in relation to the most relevant next steps.

**Vascular cognitive impairment in DSM-V**

The fifth edition of DSM, published in 2013 by the American Psychiatric Association, introduced major changes to the chapter referred to in DSM-IV as ‘Dementia, delirium, amnestic, and other cognitive disorders’ [13]. One such change concerns the used nomenclature; the chapter being referred to as ‘Neuropsychiatric Disorders’ recommends replacing the term dementia with that of ‘major neuropsychiatric disorder’ (NCD). Two reasons are stated for this change, firstly, dementia is wrongly attributed only to older populations, while it can appear in young adults (e.g. in cases of traumatic brain injury or HIV infection), and, secondly, NCD is a broader definition – individuals with substantial decline in a single domain can receive this diagnosis as opposed to the definition of dementia, which requires a decline in at least two cognitive domains (memory and another domain) [14]. Another substantial change concerns the inclusion of a less severe level of cognitive impairment named mild NCD, which, in DSM-IV, was subsumed under cognitive disorder not otherwise specified. This addition is in line with the current trends in terms of the optimal therapeutic intervention in the very early or pre-symptomatic stages of at-risk individuals for dementia. However, it may also have wide economic and public health implications, adding millions of potential new drug consumers, worldwide [15].

DSM-V also attempts to minimise the use of the ‘not otherwise specified’ category, and stresses the need to identify the presumed underlying cause of the syndrome. Thus, the first step in the diagnostic process is to differentiate between normal neurocognitive function and mild and major NCD, followed by a second step to assign an etiological category such as Alzheimer’s NCD, vascular NCD or dementia with Lewy bodies (DLB) NCD. In distinguishing among etiological subtypes, additional diagnostic markers are required, such as neuroimaging studies (magnetic resonance imaging (MRI) and positron emission tomography) and other biomarkers. DSM-V evolved from text descriptions of NCD to
‘operationalised’ criteria, so that vascular and other non-AD forms of NCD can now be specifically diagnosed.

Retaining the diagnosis of major or mild vascular NCD implies that cerebrovascular disease is the dominant (if not exclusive) pathology leading to cognitive deficits. DSM-V suggests that such a link is established by determining that either the onset of cognitive deficits is temporally related to one or more cerebrovascular events or that evidence of cognitive decline is prominent in complex attention processes (including processing speed) and frontal-executive function. Furthermore, there should be evidence of the presence of cerebrovascular disease from the history, physical examination and/or neuroimaging to account for the neurocognitive deficits. Finally, it is required that the clinical manifestations are not better explained by any other brain or systemic disorder. In situations where the above criteria are not fully met, DSM-V proposes to use the term of ‘possible’ or ‘probable’ vascular NCD.

Whilst the new multi-dimensional approach, integrating early clinical stages and operationalising aetiologic categories, has been well received, the use of positive biomarker data has not been widely adopted in clinical practice. Current diagnostic criteria do not include quantifiable measures for core pathological changes such as degree of small vessel disease (SVD) and many neuroimaging standards for research use have yet to be validated for clinical applications [10]. Furthermore, the lack of a gold standard for measuring processing speed and executive function hampers the standardised assessment of relevant neurocognitive deficits. The diagnosis of VCI in most clinical settings worldwide still relies on traditional descriptive phenomenology (clinical signs and symptoms) and on the exclusion of other possible aetiologies [16]. It is expected that these criteria will be further updated as new knowledge becomes available, both in the areas of neurocognitive testing and biomarkers.

Neuropathology: vascular dementia versus dementia with mixed pathologies

It has to be emphasised that the neuropathological diagnosis of VaD remains challenging in the absence of commonly accepted neuropathological criteria. Three main diseases of cerebral blood vessels can contribute to vascular dementia, namely atherosclerosis (AS; large- to medium-sized arteries), SVD (small arteries and arterioles) and cerebral amyloid angiopathy (CAA; arteries, capillaries and rarely veins). AS, SVD and CAA can cause different types of cerebrovascular lesions, including brain infarcts, white matter lesions and cerebral haemorrhages (Fig. 1). Large infarcts can be caused by thrombotic (AS) or thromboembolic (AS, extracranial AS, cardiogenic) occlusion of the vessel’s lumen. Lacunar infarcts are frequently caused by SVD-related vessel occlusion and microinfarcts are often related to SVD (white matter) and CAA (cortex). Based on the pattern of cerebrovascular lesions, three types of dementias associated with cerebrovascular disease may be distinguished, namely multi-infarct dementia, strategic infarct dementia and subcortical vascular encephalopathy (Binswanger’s disease).

In post mortem studies, the prevalence of pure VaD is very low; in a recently reported large series of 6205 participants, only 124 cases (1.9 %) showed cerebrovascular disease as the only morphologic substrate for clinical dementia, compared to > 15 % reported in clinical studies [17]. This discrepancy may be related to the widely held assumption that white matter hyperintensities on MRI are invariably associated with SVD, while recent studies suggest that these are usually associated with cortical neurodegenerative pathology in AD [18] and may also be associated with increased cerebral amyloid load [19]. However, limited cerebrovascular disease is often found in brains of elderly individuals with and without dementia and it is becoming increasingly clear that the ageing brain is characterised by the presence of multiple pathologies rather than the characteristic neuropathological features of one single neurodegenerative disease only. For instance, limited Lewy body pathology is seen in over 40 % of AD patients and DLB virtually always shows limited AD pathology [20], whilst a TDP-43 pathology has been demonstrated in over 50 % of AD cases, having a rather distinct topographical spreading pattern affecting the clinical presentation [20]. Nevertheless, the examples above should not be interpreted as ‘mixed dementia’ cases, where the presence of two distinct neurodegenerative diseases fulfilling all neuropathological criteria for each disease (e.g. AD and DLB) must be present [21]. Therefore, AD associated to limited cerebrovascular pathology should not be referred to as mixed dementia. However, we should be aware that even in cases that both clinically and neuropathologically fulfil the criteria for a single dementing disease, the presence of additional pathologies is likely. While the extent and severity of such additional neuropathological lesions is not sufficient to cause dementia, they may influence clinical symptoms and contribute to the pathogenesis of dementia, but their respective impact remains to be elucidated.

Risk factors and epidemiology

An important cornerstone in understanding dementia and in developing preventive and interventional strategies is to first unravel the risk factors of disease, especially those that are potentially modifiable. Therefore, herein, we will consider lifestyle and environmental factors and not dwell into genetic risk factors. Interestingly, although AD and VaD, as well as their pre-dementia counterparts mild cognitive impairment due to AD and vascular mild cognitive impairment, are still considered distinct entities, their risk factor profiles overlap substantially. Several large
population-based cohort studies (such as the Framingham Heart Study, Rotterdam Study and the Cardiovascular Health Study) have shown that established vascular factors (such as hypertension, diabetes mellitus, smoking and hyperlipidaemias) are risk factors of dementia, including AD as well as VaD [11]. Additionally, a range of clinical cardiac diseases are also independent risk factors of dementia, including atrial fibrillation [12], myocardial infarction [13] and heart failure [15]. More recently, markers of subclinical cardiac dysfunction have been linked to clinical dementia as well as preclinical brain damage identified on MRI [16].

Taken together, this evidence has formed the basis of two important research questions that have shaped epidemiological research on dementia in recent years. First, what proportion of the total burden of dementia is, in fact, caused by vascular risk factors? Second, if vascular factors are important in dementia, including AD, has improved cardiovascular health in recent decades had an effect on dementia occurrence?

Several studies have now shown that up to a third of all dementia cases can be attributed to cardiovascular risk factors [17–19]. This proportion is not restricted to VaD cases, but in fact includes all dementia cases, the majority of which may be due to AD. Importantly, this indicates that, if cardiovascular risk factors could entirely be removed from a population, theoretically, a third of all dementia cases would be preventable. This then leads to the second question of whether improvement of cardiovascular risk management has had an effect on dementia occurrence over the last few decades. Already in 2012, the Rotterdam Study presented evidence suggesting that the incidence of dementia was lower in the period 2000–2005 compared to 1990–1995 [21]; this finding was subsequently corroborated in several other Western studies [22–24] and the decrease seems to be attributable to better cardiovascular prevention. Indeed, a recent lifestyle intervention randomised controlled trial (RCT) provided, for the first time, direct evidence of a putative preventive effect of better cardiovascular control on cognitive decline.
If these results are further supported by a number of on-going non-pharmacological lifestyle intervention RCTs, there will be important worldwide public health implications in formulating effective preventive strategies in the wider population.

Cerebrospinal fluid (CSF) markers
Biomarkers can be measured in a wide range of body fluids, including blood, urine and saliva, but the CSF has been studied most extensively in relation to cerebral nervous system disorders because it often reflects biochemical processes in the brain more accurately compared to markers in the periphery. Nevertheless, CSF biomarker studies have been scarce for VCI, compared to AD. Some biomarker candidates, such as matrix metalloproteinases [26], have been proposed, but the evidence thus far remains unconvincing.

Because of the significant overlap between AD and cerebrovascular pathology, the established AD protein markers total-tau, phosphorylated-tau and amyloid-beta (Aβ)_{42} may be promising candidates for VCI/VaD. In a recently reported evaluation of over 5000 patients with dementia in Sweden [27], VaD and AD were statistically assigned to two independent clusters when a combination of all three AD markers was used for the classification. Approximately 15% of VaD and 60% of mixed dementia cases had AD-typical CSF biomarker profiles. Interestingly, over 50% of VaD cases had low Aβ_{42} concentrations, which may suggest the presence of concomitant Aβ pathology. The CSF measurements in this study were performed in clinical practice and might therefore have influenced the clinical diagnostic process, introducing a risk of circular reasoning and highlighting the need of prospective biomarker studies in VCI. Overall, these findings support the notion that a combined analysis of the three established AD CSF markers may be most useful in the differential diagnosis of VaD and VCI in more general terms.

In addition to the search for reliable cerebrovascular biomarkers, the contribution of cerebrovascular changes to the pathophysiology of AD and other late-onset dementias is increasingly being recognised [28]. Therefore, the development and validation of vascular biomarkers may, indeed, have diagnostic applications in AD and other dementia types, in addition to VCI. This notion is highlighted by the two-hit vascular hypothesis of AD [29], which proposes that microvascular damage may be the initial insult that leads to the dysfunction of the blood–brain barrier and/or decreased brain perfusion resulting in secondary neuronal injury and paving the way for the accumulation of neurotoxic Aβ oligomers. A leakage of neurotoxic proteins into the brain results from blood–brain barrier disruption, followed by a response from microglia and astrocytes, angiogenesis, and neuro-inflammation. These processes can promote white-matter damage, formation of toxic tau neurofibrillary tangles, loss of dendritic spines and Aβ accumulation. Despite the suspected linkage between vascular and AD pathology, the contribution of vascular changes to AD pathophysiology has not been adequately addressed in most studies of AD pathophysiology. The majority of biomarker studies are narrow in scope, investigate only a single category of brain injury or exclude certain patient groups, e.g. those with significant vascular risk factors or damage. In order to successfully develop new improved biomarkers for VCI and AD, future studies will need to be more comprehensive, both in terms of the targeted biomarkers and patient populations.

Neuroimaging of vascular changes
Structural neuroimaging techniques are of pivotal importance for the differential diagnosis of VaD, but also for elucidating the pathophysiological mechanisms surrounding the development of small vascular lesions in brain aging. In routine clinical settings, computed tomography (CT) and MRI provide evidence of vascular lesions that are rarely specific of a given diagnostic entity with the marked exception of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). In CADASIL, there are subcortical white matter lesions affecting the temporal pole and hyperintensity signals on T2-weighted images mainly in pons in the absence of low intensity T1 signals in deep brain stem and cerebellum [30].

Besides these rare cases, it is well established that most clinically overt VCI cases evolve progressively over several years via the accumulation of small vascular and microvascular lesions, mainly in subcortical regions. Subsequently, the construct of VCI has been proposed to capture the entire spectrum of cognitive disorders associated with all forms of cerebral vascular brain injury, not solely stroke, ranging from mild cognitive impairment through to fully developed dementia. As already proposed by the NINDS-AIREN criteria and subsequently confirmed by neuroimaging studies, a substantial percentage of VaD cases is due to SVD affecting small cerebral arterioles, capillaries and venules possibly due to intrinsic arteriolar occlusive disorder [31]. Although the small vessels are not easily identifiable, detailed neuroimaging may allow for tracking of their pathology in the human brain. The main imaging features of SVD visible on 1.5 T and 3 T MRI scans are acute lacunar infarcts, neurologically silent lacunes, white matter hyperintensities, increased perivascular spaces and microbleeds [32, 33] (Figs. 2 and 3). Microinfarcts are strongly related to cognitive decline, yet they are detectable only at higher field strengths, usually only available in research facilities [34]. Lacunar strokes correspond to lesions less than 20 mm in axial diameter; old
lacunes are small cavities between 3 and 15 mm in diameter located in the deep grey or white matter [27]. Both these lesions are known to affect cognition, mainly in pure VaD cases [35]. On MRI scans, they are detected by increased signal on diffusion-weighted imaging, reduced signal on an apparent diffusion coefficient map, increased T2-weighted imaging, reduced signal on T1-weighted MRI, and low attenuation on CT scanning. White matter hyperintensities are areas of decreased attenuation in CT scans, increased signal on T2 and fluid-attenuated inversion recovery sequences, and in some cases decreased on T1-weighted MRI scans. Present in periventricular and deep white matter, in the basal ganglia (deep grey matter) and more rarely in pons and cerebellum, they signal the progression of SVD and their severity is related to the emergence of VaD in clinical samples [36]. Increased perivascular spaces are visible on T2- and T1-weighted MRI scans mostly in basal ganglia and subcortical white matter. Strongly related to white matter hyperintensities, they are very frequent in old age but the increase of their number is related to VCI [37]. Finally, cortical microbleeds are punctiform areas of hypointensity on T2- or susceptibility-weighted sequences, of up to 1 cm of diameter. An impressive number of studies have attempted to define their cognitive significance with conflicting results [38–40]; their negative impact on cognition is highly likely in VaD, but much less in mixed cases.

In addition to microvascular and small macrovascular lesions, recent contributions pointed to the presence of white matter microstructure changes assessed with diffusion tensor imaging (DTI) at the early stages of cognitive decline (reviewed in [41]). Several DTI-derived parameters were taken into account, including fractional anisotropy and longitudinal, radial and mean diffusivity. Tract-based spatial statistics were used to project DTI-derived data onto a mean tract skeleton by using non-linear registration. The tract skeleton is the basis for voxel-wise cross-subject statistics and reduces potential misregistrations as the source for false-positive or false-negative analysis results. Applying voxel-wise DTI analyses, a significant decrease of fractional anisotropy values was detected in hemispheric deep white matter and corpus callosum in patients with VCI compared to healthy controls [42]. Although still in its infancy, the automatic processing of DTI data at an individual level using support vector machine analysis may allow identification of the very first signs of biological compromise of white matter in VCI.
Familial forms of vascular dementia

Herein, we briefly summarise the available data in relation to clinical diagnostic criteria. The genetic underpinning of cerebrovascular changes has been less well studied compared to other dementia forms, such as AD [43]. However, in most genetic studies in sporadic AD, the inclusion criteria are such that they may allow a variable number of cases and/or of mixed pathologies to be included. Of note, the upper age limit of most of these studies is in excess of 80 years, when mixed pathologies are common. Thus far, studies have failed to characterise the heritability of sporadic VCI but there have been several reports on rare monogenic conditions involving cerebral small vessels and predisposing to ischemic and/or hemorrhagic stroke and diffuse white matter disease. In these disorders, the primary genetic defect (autosomal dominant, recessive or X linked) may alter endothelial cells of microvessels leading to impairment of deep brain vascularisation and resulting in clinical manifestations such as subcortical leucoencephalopathy and episodes of stroke.

A diagnosis of hereditary cerebral small vessel disease has to be considered in familial cerebrovascular disorders occurring mainly in young adulthood; it can be distinguished from sporadic cerebral microangiopathy due to the presence of a high vascular risk load. The most important clinical entities are CADASIL, cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy, COL4A1-related cerebral small vessel diseases, autosomal dominant retinal vasculopathy with cerebral leuco-dystrophy, and Fabry disease. The main clinical and genetic characteristics of these disorders are presented in Table 1. Although they have variable phenotypes and different defective genes, all these diseases cause arteriopathy and microvascular disintegration leading to VCI. In these cases, genetic, biochemical or pathological analyses will confirm the clinical suspicion and are very useful in clinical practice (Table 2) [4, 44, 45]. Specific substitution treatment with recombinant enzymes is available only for Fabry's disease, and treatment mainly improves non-central nervous system organ function (kidney, heart, peripheral nerve, etc.), with little change in central neurological abnormalities because of the difficulty of the enzyme to cross the blood–brain barrier [46].

Recommendations and future perspectives

Despite significant progress in recent years, important gaps in knowledge persist in terms of the extent and granularity of dementia types and their distinct underlyng biological pathways, as well as the mechanisms underpinning cognitive deterioration. There is abundant evidence that mixed pathologies are very prevalent in patients over the age of 75 and that pure VCI is rare. It is also evident that cognitive profiles may differ between different types of dementia and that the AD-centred definition of dementia may not be appropriate for other dementia types. We have also learned, from large-scale

---

**Fig. 3** Examples of typical magnetic resonance imaging of white matter disease. *White matter lesions.* Usually attributed to chronic small vessel ischaemia, rating using the Fazekas scale. No lesions or single punctate lesion (grade 0), multiple punctate lesions (grade 1), beginning confluency of lesions (bridging, grade 2), large confluent lesions (grade 3)
clinical trials, that AD-specific treatments, such as cholinesterase inhibitors and memantine, may not show the desired effects in people with other dementias. Imaging and fluid biomarkers are useful in differentiating AD from VCI and to enrich trial populations with relatively pure cases. However, significant pathological (and presumably nosological) overlaps do exist between the diagnostic groups, even in biomarker-based clinically diagnosed cases, whereas biomarkers are still not part of the diagnostic armamentarium in the majority of clinical dementia settings worldwide.

In view of these significant gaps of knowledge, further research is urgently required to address key issues. Firstly, our understanding of the key pathogenic mechanisms of VCI is far less developed than for AD. They include not only the determinants of vascular burden in the human brain but also its indirect consequences (increased neuro-inflammation, altered oxidative stress regulation, changes in brain reactivity) over time. Further, shared patho-mechanisms between VCI and AD remain poorly understood in view of their complexity. Secondly, large population-based studies have identified important risk factors for late-life dementia and some are, indeed, modifiable, thus promising targets for prevention and treatment strategies. This important hypothesis now needs to be scrutinised in appropriately powered prospective pharmacological and non-pharmacological RCTs. Thirdly, fragmented research initiatives must be brought together in coordinated international research programs in order to optimally utilise human, financial and other resources and increase power. For example, large-scale prospective longitudinal studies aimed at identifying genetic and other risk factors may also identify predictive and diagnostic markers. The accumulated information may well allow for a better delineation and definition of dementia types, such as AD and VCI and, potentially, their subtypes. We have learned from other disease areas, such as cancer, that this is a pre-condition for the discovery and

Table 1 Characteristics of important inherited cerebral small vessel diseases

| Disease                    | Gene          | Protein                        | Onset age | Clinical features                                                                 |
|----------------------------|---------------|--------------------------------|-----------|-----------------------------------------------------------------------------------|
| CADASIL                    | NOTCH3        | Notch3 receptor protein         | 30–40 years | Progressive dementia, mood disorders, migraines, recurrent subcortical cerebral, infarction and leucoencephalopathy, mainly in temporal poles |
| CARASIL                    | HTRA1         | HTRA1, serine protease          | 20–30 years | Mood changes, pseudobulbar palsy, mental dysfunction, scalp alopecia in the teen, acute mid-to-lower back pain and subcortical white matter changes on MRI |
| COL4A1                     | COL4A1        | Type IV collagen α1-chain       | All ages  | Ischemic stroke, intracerebral haemorrhage, retinal arteriolar tortuosity, cataracts, glaucoma, anterior segment dysgenesis of the eye (Axenfeld–Rieger anomaly), muscle cramps, Raynaud phenomena, kidney defects |
| RVCL                       | TREX1         | Trex1 DNAse III                 | 30–40 years | Retinal vasculopathy, TIA, strokes, cognitive dysfunction, headaches, personality disorders, Raynaud’s phenomena, liver and kidney dysfunction |
| Fabry disease              | alpha-GalA    | Alpha-galactosidase (α-GalA)    | Childhood | Classic form: acroparesthesias, angiokeratomas, hypohidrosis, characteristic corneal and lenticular opacities, proteinuria, peripheral neuropathy, TIA and stroke, heart disturbances and cardiomyopathy. Heterozygous females: milder symptoms, later onset |

Table 2 In vivo diagnosis of genetic small vessel diseases

| Disease                    | Genetic investigations | Pathological investigations | Biochemical investigations |
|----------------------------|------------------------|----------------------------|---------------------------|
| CADASIL                    | NOTCH3 mutations       | Evidence of granular osmiophilic material in affected arterioles | None                       |
| CARASIL                    | HTRA1 mutations        | N/A                        | N/A                       |
| COL4A1                     | COL4A1 type IV collagen α1-chain | N/A                        | N/A                       |
| RVCL                       | TREX1 DNAse III        | N/A                        | N/A                       |
| Fabry disease              | Alpha Gal-A gene mutations | Lysosomal abnormalities in tissues | Deficiency a-galactosidase activity in serum, urine, leukocytes, tissues; abnormalities in urinary and tissues glycolipids |
development of effective new medicines. Finally, the pre-

dementia and pre-clinical stages of VCI have to be defined

more precisely and we propose that the term vascular
mild cognitive impairment is used in line with the concept of
mild cognitive impairment due to AD to characterise
the early clinical stage that precedes VaD.

Acknowledgments

The authors would like to thank Kirsty E McAleese for contributing the

neuropathological images.

Funding

There was no external funding source for this paper.

Authors’ contribution

All authors contributed to performing the literature review and in drafting,
reviewing and editing the manuscript. All authors read and approved the
final manuscript.

Competing interests

The authors declare that they have no competing interests.

Author details

1Neuropopidemiology and Ageing Research Unit, School of Public Health,
Faculty of Medicine, The Imperial College of Science, Technology and
Medicine, Charing Cross Hospital, St Dunstan’s Road, W6 8RP London, UK.
2Department of Psychiatry and Psychotherapy, Technische Universität
München, Ismaninger Str. 22, 81675 München, Germany.
3Cognitive Impairment and Dementia Service, West London Mental Health NHS Trust,
Lakeside Mental Health Unit, West Middlesex University Hospital,
Twickenham Road, TW7 6FY London, UK.
4Department of Psychiatry, Psychotherapy, Technische Universität
München, Ismaninger Str. 22, 81675 München, Germany.
5Department of Psychiatry, Tel Aviv Sourasky Medical Center, Haim Weizman St 6, Tel Aviv-Yafo 64239, Israel.
6Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel.
7Institute of Neuroscience, Newcastle University, Campus for Ageing and
Vitality, NE4 5LP Newcastle upon Tyne, UK.
8Department of Psychiatry, University of Geneva School of Medicine, 2 rue Verte, 1205 Geneva,
Switzerland.
9Departments of Epidemiology, Radiology and Neurology, Erasmus MC, 3000 MC Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
10Department of Medicine, Surgery and Neuroscience, University of Siena,
Viale Bacci 2, 53100 Siena, Italy.
11Unit of Neurology of Memory and Language, Centre de Psychiatrie et Neurosciences, INSERM UMR S894, Centre Hospitalier Sainte-Anne et Université Paris Descartes, Sorbonne Paris Cité,
75013 Paris, France.

Received: 27 May 2016 Accepted: 14 October 2016

References

1. Kalaria RN, Akinseye R, Isha M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016;1862(5):915–25.
2. Iadeola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):1844–66.
3. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;115(12):797–811.
4. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology. 1992;42(2 Pt 1):473–80.
5. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DM. Research criteria for subcortical vascular dementia in clinical trials. J Neuro Transm Suppl. 2000;59:23–30.
6. Sachdev PS, Chen X, Brodaty H, Thompson C, Attendorf A, Wen W. The determinants and longitudinal course of post-stroke mild cognitive impairment. J Int Neuropyschol Soc. 2009;15(6):915–23.
7. Stephan BC, Matthews FE, Khaw KT, Dufool C, Brayne C. Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND). Alzheimer’s Res Ther. 2009;11(4).
8. Matz K, Teusch Y, Firlinger B, Dachenhausen A, Keindl M, Seyfang L, Tuomilehto J, Brainin M ASPS Study Group. Multidomain lifestyle interventions for the prevention of cognitive decline after ischemic stroke: randomized trial. Stroke. 2015;46(10):2874–80.
9. O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JR, Ballard C, DeCarli C, Gorelick PB, et al. Vascular cognitive impairment. Lancet Neurol. 2002;2(9):89–98.
10. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O’Brien JT, Barkhof F, Benavente OR, et al. Neuroradiographic standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.
11. de Bruijn RF, Iikam MA. Cardiovascular risk factors and future risk of Alzheimer’s disease. BMC Med. 2014;12:30.
12. de Bruijn RF, Heeringa J, Wolters FJ, Franco OH, Stricker BH, Hofman A, Koudstaal PJ, Iikam MA. Association between atrial fibrillation and dementia in the general population. JAIME Neurol. 2015;2(11):1288–94.
13. Iikam MA, van Oijen M, de Jong FJ, Kors JA, Koudstaal PJ, Hofman A, Witterman JC, Breiter MW. Unrecognized myocardial infarction in relation to risk of dementia and cerebral small vessel disease. Stroke. 2008;39(9):1421–6.
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th Edition. Arlington, American Psychiatric Association, 2013.
15. Rusanen M, Kivipelto M, Levalahti E, Jukonen E, Soininen H, Ngandu T. Heart diseases and long-term risk of dementia and Alzheimer’s disease: a population-based CAIDE study. J Alzheimers Dis. 2014;42(1):183–91.
16. de Bruijn RF, Portegies ML, Leening MJ, Bos MJ, Hofman A, van der Lugt A, Nisren WJ, Vennouli JW, Franco OH, Koudstaal PJ, et al. Subclinical cardiac dysfunction increases the risk of stroke and dementia: the Rotterdam Study. Lancet Neurol. 2015;14(8):833–40.
17. de Bruijn RF, Bos MJ, Portegies ML, Hofman A, Franco OH, Koudstaal PJ, Iikam MA. The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. BMC Med. 2015;13:132.
18. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet. 2011;100(9819):28–30.
19. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.
20. Attems J, Jellinger K. Neuropathological correlates of cerebral multimorbidity. Curr Alzheimer Res. 2013;10(6):569–77.
21. Schijls EM, Verhaaren BF, Koudstaal PJ, Hofman A, Iikam MA, Breiter MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78(19):1456–63.
22. Qi C, von Strauss E, Backman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013;80(20):1888–94.
23. Lobo A, Paz M, Dias J, Barreto MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78(19):1456–63.
24. Qi C, van Strauss E, Backman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013;80(20):1888–94.
25. Lobo A, Paz M, Dias J, Barreto MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78(19):1456–63.
26. Schijls EM, Verhaaren BF, Koudstaal PJ, Hofman A, Iikam MA, Breiter MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78(19):1456–63.
27. Qi C, von Strauss E, Backman L, Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology. 2013;80(20):1888–94.
26. Bjerkø M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U. Cerebrosellar fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis. 2011;27(3):665–76.

27. Sinka L, Kovari E, Gold G, Hof PR, Herrmann FR, Bousset C, Giannakopoulos P. Small vascular and Alzheimer disease-related pathologic determinants of dementia in the oldest-old. J Neuropathol Exp Neurol. 2010;69(12):1247–55.

28. Vickrey BG, Brott TG, Koroshetz WJ. Stroke Research Priorities Meeting Steering Committee and the National Advisory Neurological Disorders and Stroke Council; National Institute of Neurological Disorders and Stroke. Research priority setting; a summary of the 2012 NINDS Stroke Planning Meeting Report. Stroke. 2013;44(8):2339–42.

29. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723–38.

30. Chabriat H, Mirra S, Levy C, Vahedi K, Taillia H, Ilba-Zizen MT, Joutel A, Tournier-Lasserve E, Bousser MG. Brain stem MRI signal abnormalities in CADASIL. Stroke. 1999;30(2):457–9.

31. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689–701.

32. Rost NS, Rahman RM, Biffi A, Smith EE, Kanakis A, Fitzpatrick K, Lima F, Worrall BB, Meschia JF, Brown Jr RD, et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology. 2010;75(19):1670–7.

33. O’Sullivan M. Imaging small vessel disease: lesion topography, networks, and cognitive deficits investigated with MRI Stroke. 2010;41(10 Suppl):S154–8.

34. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol. 2012;11(3):272–82.

35. Yi T, Yu JR, Zhang YP, Li T. Analysis on correlation of white matter lesion and lacunar infarction with vascular cognitive impairment. Int J Clin Exp Med. 2015;8(8):14119–22.

36. Kim S, Choi SH, Lee YM, Kim MJ, Kim YD, Kim JY, Park JH, Myung W, Na HR, Han HJ, et al. Periventricular white matter hyperintensities and the risk of dementia: a CREDO study. Int Psychogeriatr. 2015;27(12):2069–77.

37. Hansen TP, Cain J, Thomas O, Jackson A. Dilated perivascular spaces in the Basal Ganglia are a biomarker of small-vessel disease in a very elderly population with dementia. AJNR Am J Neuroradiol. 2015;36(5):893–8.

38. Miwa K, Tanaka M, Okazaki S, Yagita Y, Sakaguchi M, Mochizuki H, Kitagawa K. Multiple or mixed cerebral microbleeds and dementia in patients with vascular risk factors. Neurology. 2014;83(7):646–53.

39. De Reuck JL, Deramecourt V, Auger F, Durieux N, Cordonnier C, Devos D, Defebvre L, Moreau C, Capparos-Lefebvre D, Pasquier F, et al. The significance of cortical cerebral microbleeds and microinfarcts in neurodegenerative and cerebrovascular diseases. A post-mortem 7.0-tesla magnetic resonance study with neuropathological correlates. Cerebrovasc Dis. 2015;39(2):138–43.

40. Ye BS, Seo SW, Kim JH, Kim GH, Cho H, Noh Y, Kim HJ, Yoon CW, Woo SY, Kim SH, et al. Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology. 2015;85(19):1687–93.

41. Zhang B, Xu Y, Zhu B, Perneczky et al. Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology. 2015;85(19):1687–93.

42. Otsuka Y, Yamauchi H, Sawamoto N, Iseki K, Tomimoto H, Fukuyama H. Small vascular disease-related pathologic determinants of dementia in the oldest-old. J Neuropathol Exp Neurol. 2010;69(12):1247–55.

43. Federicio A, Di Donato I, Bianchi S, Di Palma C, Taglia I, Dotti MT. Hereditary cerebral small vessel diseases: a review. J Neurol Sci. 2012;322(1–2):25–30.

44. Tang RY, Markus HS. Monogenic causes of stroke: now and the future. J Neurol. 2015;262(12):2601–16.

45. Rombach SM, Smid BE, Linthorst GE, Dijkstra MF, Hollaar CE. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014;37(3):341–52.